Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to 9.03%.

  • Anika Therapeutics' EBITDA Margin rose 897600.0% to 9.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 28.61%, marking a year-over-year increase of 832500.0%. This contributed to the annual value of 47.72% for FY2024, which is 203000.0% up from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' EBITDA Margin is 9.03%, which was up 897600.0% from 9.29% recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' EBITDA Margin registered a high of 2151.74% during Q4 2023, and its lowest value of 98.8% during Q3 2024.
  • Its 5-year average for EBITDA Margin is 104.94%, with a median of 9.29% in 2025.
  • As far as peak fluctuations go, Anika Therapeutics' EBITDA Margin surged by 20134600bps in 2023, and later tumbled by -22267300bps in 2024.
  • Quarter analysis of 5 years shows Anika Therapeutics' EBITDA Margin stood at 17.29% in 2021, then surged by 900bps to 138.28% in 2022, then skyrocketed by 1456bps to 2151.74% in 2023, then plummeted by -103bps to 74.99% in 2024, then skyrocketed by 88bps to 9.03% in 2025.
  • Its EBITDA Margin stands at 9.03% for Q3 2025, versus 9.29% for Q2 2025 and 16.02% for Q1 2025.